Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) shares traded down 11.7% on Monday . The company traded as low as $0.47 and last traded at $0.48. 1,319,186 shares traded hands during trading, an increase of 72% from the average session volume of 766,801 shares. The stock had previously closed at $0.54.
A number of analysts have commented on ATNM shares. Oppenheimer set a $5.00 target price on Actinium Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, February 26th. Zacks Investment Research raised Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 target price for the company in a report on Monday, April 1st. Finally, Maxim Group set a $3.00 target price on Actinium Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, February 5th. Five analysts have rated the stock with a buy rating, Actinium Pharmaceuticals presently has an average rating of “Buy” and an average target price of $3.50.
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last issued its earnings results on Tuesday, March 19th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.06).
ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/04/15/actinium-pharmaceuticals-atnm-shares-down-11-7.html.
About Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)
Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.
Further Reading: What is a Candlestick Chart?
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.